1. P03.20 A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment. (1st October 2020) Authors: Gsottberger, F; Brandl, C; Petkovic, S; Nitschke, L; Mackensen, A; Müller, F Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P09.14 Blocking counterregulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities. (1st October 2020) Authors: Gsottberger, F; Meier, C; Petkovic, S; Mellenthin, L; Krumbholz, M; Metzler, M; Mackensen, A; Müller, F Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 2 Page Start: A59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Reduced cytotoxicity by mutation of lysine 590 of Pseudomonas exotoxin can be restored in an optimized, lysine-free immunotoxin. Issue 1 (21st February 2022) Authors: Ammon, A; Mellenthin, L; Emmerich, C; Naschberger, E; Stürzl, M; Mackensen, A; Müller, F Journal: Immunotherapy advances Issue: Volume 2:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗